{"id":21118,"date":"2013-04-01T12:30:53","date_gmt":"2013-04-01T12:30:53","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=21118"},"modified":"2013-05-29T20:33:41","modified_gmt":"2013-05-29T20:33:41","slug":"20th-conference-on-retroviruses-and-opportunistic-infections-croi-3-6-march-2013-atlanta","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/21118","title":{"rendered":"20th Conference on Retroviruses and Opportunistic Infections (CROI)  3-6 March 2013, Atlanta"},"content":{"rendered":"<h2>Introduction<\/h2>\n<p><strong>The annual CROI continues to be the most important HIV scientific meeting covering the diversity of basic and clinical science.<\/strong><\/p>\n<p>Also, both the main conference and a pre-meeting programme of lectures for new investigators are promptly posted online as open access webcasts.<\/p>\n<p><a href=\"http:\/\/www.retroconference.org\">http:\/\/www.retroconference.org<\/a><\/p>\n<p>This year the meeting resulted in wide press coverage of the case of a baby who appears functionally cured following 18 months treatment initiated within two days of birth. But the conference included a wealth of other studies covering HIV treatment and prevention. This included studies reporting new drugs, new strategies (especially treatment during early infection), paediatrics, TB and other OIs &#8211; principally in resource limited settings &#8211; and exciting results for hepatitis C coinfection.<\/p>\n<p>Reports in this issue of HTB include:<\/p>\n<ul>\n<li><a href=\"https:\/\/i-base.info\/htb\/21065\">ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21069\">ARV pipeline: long-acting formulations &#8211; rilpivirine, GSK-744 and nanoformulations<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21182\">Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21184\">Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21186\">Pharmacokinetics and acceptability of lopinavir\/ritonavir sprinkles in children aged 1 to 4 years<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21235\">Pharmacokinetics of currently available antiretroviral options for young children<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21191\">Safety of transplacental raltegravir in neonates and washout pharmacokinetics<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21193\">Tenofovir use in children<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21201\">ddI resistance in South African children failing an abacavir or d4T based first-line regimens<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21203\">Statin use in HIV positive people<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21095\">RIFAQUIN study demonstrates once-weekly dosing during continuation phase of TB treatment<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21097\">Combining Xpert and LAM urine testing improves TB diagnostic sensitivity<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21092\">Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21072\">Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21075\">Tenofovir DF ring protects macaques from vaginal exposure<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21077\">VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21080\">Further studies on how male circumcision may reduce HIV transmission<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/21208\">Report of a functional cure in an HIV infected infant<\/a><\/li>\n<\/ul>\n<p>Further reports will be continue in the next issue of HTB, with pre-press articles available earlier online.<\/p>\n<p>Unless stated otherwise, references are to the Programme and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta.<\/p>\n<p><a href=\"http:\/\/www.retroconference.org\">http:\/\/www.retroconference.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our first reports from CROI 2013: new drugs, paediatric studies, TB coinfection, PrEP, prevention and the cured infant<\/p>\n","protected":false},"author":3,"featured_media":21218,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,173],"class_list":["post-21118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-conference-reports","tag-conference-index","tag-croi-2013"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=21118"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/21218"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=21118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=21118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=21118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}